Today's Rundown President Trump to pick MD Anderson Cancer Center doctor as next FDA commish: WSJ AstraZeneca dumps phase 3 renal cell carcinoma program NIH, Gates Foundation commit $200M to cure HIV, sickle cell [Sponsored] Advancing Site-Sponsor Relationships Job cuts at Acorda, Alkermes as they scramble to slash spending Novartis-partnered TrialSpark pens 'digital' trial collab with Limbix Featured Story | | | Thursday, October 24, 2019 President Donald Trump is set to pick oncologist Stephen Hahn, currently chief medical executive at MD Anderson Cancer Center in Houston, as the next FDA commissioner, forgoing current leader Ned Sharpless. |
|
|---|
|
Top Stories Thursday, October 24, 2019 AstraZeneca has scrapped development of savolitinib as a monotherapy treatment for papillary renal cell carcinoma. The phase 3 program was one of five projects removed from AstraZeneca’s pipeline in conjunction with its second-quarter results. Thursday, October 24, 2019 The National Institutes of Health and the Bill & Melinda Gates Foundation have each committed $100 million to advance cures for HIV and sickle cell disease. The goal is to start testing in vivo gene-based treatments for the diseases in humans within 10 years and ultimately to make them available at a cost that enables global use. Monday, October 21, 2019 Clinical trials involve massive complexity and, often, systems that lack consistency and discipline. With a new perspective to an old problem, WCG coordinates the execution of six proven strategies to dramatically and consistently bring clinical studies to launch faster and at a lower cost. Thursday, October 24, 2019 Jobs are on the chopping block at Acorda Therapeutics and Alkermes as each company works to cut costs and stay alive. Acorda will lay off about one-quarter of its employees, while Alkermes will cut 160 jobs. Thursday, October 24, 2019 Clinical study tech company TrialSpark teamed up with mental health firm Limbix to work on a new “digital therapeutic” for adolescent depression. | | Better than the other transgenics.
Better than in vitro display.
Better than humanization. AlivaMabTM Mouse from Ablexis delivers quality, speed and value in generating development-ready antibodies that meet your target product profile. Contact us at [email protected] to learn more. ablexis.com |
Resources Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 